Denmark medical cannabis sales post a positive quarter thanks to Epidiolex

Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ cannabis drug Epidiolex.

DEA removes cannabis drug Epidiolex from controlled substances list

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered a controlled substance, providing a boost to its manufacturer’s stock price.

Can DEA-backed cannabis growers strike gold via drug development?

The cannabis industry hit a possible milestone in March when Bright Green Corp., a Florida company with “conditional” approval from the U.S. Drug Enforcement Administration to grow marijuana for research purposes, applied to list on the Nasdaq stock exchange.
But the move also highlights the lofty – some say unrealistic – financial ambitions of such companies.

Court tosses Canopy cannabis patent infringement lawsuit against GW Pharma

A Texas court has dismissed a lawsuit brought by Canadian cannabis producer Canopy Growth against GW Pharmaceuticals, although Canopy has the right to appeal the ruling.

Cannabis producers cautioned against profiteering from COVID-19 research

As research broke over the past two weeks that cannabis products such as CBD, cannabinoid acids and even synthetic cannabis compounds might prevent or treat COVID-19 infections, excitement among entrepreneurs spread.

Synthetic CBD might offer protection from COVID-19, Canadian research shows

More research saying cannabinoids might protect human cells from COVID-19 was released this week by scientists in Ontario, Canada, who work with synthetic CBD.